Revenue-Based Financing in Massachusetts (2026)
Massachusetts, driven by Boston and Cambridge, is one of the most research-intensive startup economies in the country, with global strengths in biotech, healthtech, enterprise and B2B SaaS, robotics, and deep tech spun out of MIT, Harvard, and the region's universities. The state's venture market is deep and sophisticated, and equity is the default for the capital-intensive science companies that define much of the ecosystem. But Massachusetts also has a large and growing base of B2B SaaS and software businesses with strong recurring revenue, and for those companies revenue-based financing is a compelling, non-dilutive option. RBF provides capital repaid as a percentage of monthly revenue until reaching a cap, typically 1.3x to 2x the advance, letting a Boston SaaS founder fund growth without diluting equity or adding board seats. Given how expensive Massachusetts talent and lab or office space can be, the ability to access capital quickly and non-dilutively to extend runway between rounds is genuinely valuable. RBF is not a fit for pre-revenue biotech, which needs patient equity, but it is well matched to the region's software companies with predictable MRR. Founders here often use RBF to bridge between priced rounds, fund customer acquisition, or avoid raising at a flat valuation, complementing rather than replacing the equity that fuels the state's deep-tech engine.
Last updated
This guide and matching listings are refreshed from the Bootstrap Directory database as source data changes.
Data sources
Sources include Grants.gov, SAM.gov, SBIR.gov, CareerOneStop, state agencies, universities, and verified organizations.
Refresh cadence
Listings are checked weekly where source data allows, with stale or closed programs removed from public results.
Verification
Always confirm eligibility, deadlines, and award details on the official source or application page before applying.
Get alerts for this search
Create a free account, run the matching search, and save it to get new funding, grant, or training updates.
Revenue-based financing in Massachusetts
Massachusetts is famous for biotech and deep tech, but Boston and Cambridge also host a large base of B2B SaaS and software companies with strong recurring revenue. For those businesses, RBF offers non-dilutive capital repaid as a percentage of monthly revenue up to a cap. With the region's high talent and lab or office costs, the ability to access capital quickly without dilution is valuable for extending runway between rounds. RBF is best matched to software companies with predictable MRR rather than the pre-revenue science startups that rely on equity.
Is RBF right for your Massachusetts startup?
RBF suits Massachusetts companies with proven recurring revenue: B2B and enterprise SaaS with stable MRR and subscription software. Providers weigh revenue consistency, margins, and churn more than company age. The tradeoff is that the repayment cap costs more than a cheap loan and the revenue share trims near-term cash, but you retain full ownership. Pre-revenue biotech, healthtech, and robotics ventures, which dominate much of the local ecosystem, need patient equity instead and are not candidates for RBF.
RBF vs. other funding in Massachusetts
The state's deep venture market is essential for capital-intensive science companies, but equity dilutes founders and adds board oversight. Bank loans are cheaper yet slow and collateral-heavy, a poor fit for asset-light SaaS. Non-dilutive grants, including research programs, are vital for biotech but competitive and restricted. RBF sits between these for software businesses: faster and more flexible than a loan, non-dilutive unlike venture capital, and repaid in proportion to revenue. Massachusetts SaaS founders often blend RBF with equity to fund growth while limiting dilution.
Frequently Asked Questions
Is revenue-based financing a fit for Boston's biotech-heavy ecosystem?
Not for pre-revenue biotech, which needs patient equity to fund long research cycles. RBF is, however, a strong fit for the region's many B2B SaaS and software companies with recurring revenue. Those businesses can use RBF to fund growth non-dilutively, while capital-intensive science startups continue to rely on Massachusetts's deep venture market.
How does RBF work for a Massachusetts SaaS company?
A provider advances capital against your recurring revenue, and you repay a fixed percentage of monthly sales until reaching a cap, usually 1.3x to 2x the advance. For a Boston or Cambridge SaaS business with steady MRR, this aligns repayment with cash flow and avoids dilution, which is useful given the region's high talent and office costs.
Why might a Massachusetts founder choose RBF over an equity round?
The state has deep venture capital, but equity dilutes founders and adds board control. RBF is non-dilutive and fast to close, so founders use it to bridge between priced rounds, fund customer acquisition, or avoid raising at a flat valuation. Many pair it with equity to minimize overall dilution.
What revenue profile qualifies a Massachusetts startup for RBF?
Providers want a consistent track record of recurring revenue, generally several months of steady MRR and healthy gross margins, rather than a minimum company age. Strong retention and low churn improve the advance size and repayment cap. Pre-revenue research-stage companies, common in the region, do not qualify until they have demonstrable revenue.